Mednet Logo

What is your preferred second-line therapy for metastatic pancreatic cancer after progression on gemcitabine/nab-paclitaxel who are not candidates for mFOLFIRINOX?

Community PollStarted

What is your preferred second-line therapy for metastatic pancreatic cancer after progression on gemcitabine/nab-paclitaxel who are not candidates for mFOLFIRINOX?

62 physicians have voted

Join Mednetto vote and see how they answered.